Age and the Residual Risk of Cardiovascular Disease following Low Density Lipoprotein-Cholesterol Exposure

Author:

König Carola S.1ORCID,Mann Amar2,McFarlane Rob2ORCID,Marriott John2,Price Malcolm3,Ramachandran Sudarshan1456

Affiliation:

1. Department of Mechanical and Aerospace Engineering, Brunel University London, London UB8 3PH, UK

2. Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK

3. Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK

4. Department of Clinical Biochemistry, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK

5. Department of Clinical Biochemistry, University Hospitals of North Midlands, Staffordshire ST4 6QG, UK

6. School of Medicine, Keele University, Staffordshire ST5 5BG, UK

Abstract

We believe that there is sufficient evidence from basic science, longitudinal cohort studies and randomised controlled trials which validates the low-density lipoprotein cholesterol (LDL-C) or lipid hypothesis. It is important that we can communicate details of the cardiovascular disease (CVD) risk reduction that the average patient could expect depending on the scale of LDL-C decrease following lipid lowering therapy. It is also essential that residual risk (ResR) of CVD be highlighted. To achieve this aim by using existing trial evidence, we developed mathematical models initially for relative risk reduction (RRR) and absolute risk (AR) reduction and then showed that despite optimising LDL-C levels, a considerable degree of ResR remains that is dependent on AR. Age is significantly associated with AR (odds ratio: 1.02, 95% confidence intervals: 1.01–1.04) as was previously demonstrated by analysing the Whickham study cohort using a logistic regression model (age remaining significant even when all the other significant risk factors such as sex, smoking, systolic blood pressure, diabetes and family history were included in the regression model). A discussion of a paper by Ference et al. provided detailed evidence of the relationship between age and AR, based on lifetime LDL-C exposure. Finally, we discussed non-traditional CVD risk factors that may contribute to ResR based on randomised controlled trials investigating drugs improving inflammation, thrombosis, metabolic and endothelial status.

Publisher

MDPI AG

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

Reference67 articles.

1. (2023, May 14). Cardiovascular Diseases (CVDs)—World Health Organisation 11th June 2021. Available online: www.who.int/health-topics/cardiovascular-diseases#tab=tab_1.

2. Cardiovascular disease care and outcomes in West and South European countries;Timmis;Lancet Reg. Health Eur.,2023

3. Cohort Profile: The Framingham Heart Study (FHS): Overview of milestones in cardiovascular epidemiology;Tsao;Int. J. Epidemiol.,2015

4. An updated coronary risk profile. A statement for health professionals;Anderson;Circulation,1991

5. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study;Assmann;Circulation,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3